Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil
批准号:
8779665
负责人:
PHILIP O. LIVINGSTON
金额:
$22.5万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-06-15 至 2015-05-31
关键词:
AdjuvantAntibodiesAntibody FormationAntigensAttenuatedBiologicalBiological AssayCarbohydratesCharacteristicsChemicalsClinicalCommunicable DiseasesConjugate VaccinesDegenerative DisorderDevelopmentDiseaseDoseFeverHarvestImmunologic AdjuvantsImmunologicsIntellectual PropertyKeyhole Limpet HemocyaninLeadLegal patentLicensingMalignant NeoplasmsMeasurementMemorial Sloan-Kettering Cancer CenterMethodsModelingMolecularMucin-1 Staining MethodOspC proteinPeptidesPeripheralPharmaceutical PreparationsPharmacology and ToxicologyPhasePhase I Clinical TrialsPrevnarPublic HealthSafetySaponinSaponinsSeriesSmall Business Innovation Research GrantSoapbushStructureT cell responseTechnologyTestingToxic effectTreatment EfficacyTreesTrisaccharidesTriterpenesUnited StatesVaccine AdjuvantVaccinesVariantanalogbasedesignfunctional groupimmunogenicityimprovednext generationnovelpre-clinicalprotective efficacypublic health relevancescale upsugarvaccinology
中文摘要
性状(申请人提供):抗肿瘤和抗感染性疾病疫苗需要佐剂,以获得最佳的免疫原性和治疗保护效力。QS-21是一种天然皂苷组分,在引发生产性抗体和T细胞应答方面显著优于其他佐剂。它仍然是佐剂的选择,并已证明它的效力作为免疫佐剂在许多癌症,传染病和退行性疾病疫苗试验。阻碍QS-21进一步开发的问题包括不利的生物效应(限制了可耐受剂量)、化学不稳定性、Quillaja saponaria树(从中提取QS-21)的稀缺性以及这些树的收获产量的可变性。最近,我们的半合成QS-21合成方法克服了所有这些缺点。这种合成也使得分子结构单元易于用于合成修饰和截短的QS-21类似物。天然皂苷内的不稳定键被化学上坚固的官能团取代增强了分子稳定性。结合外周糖部分和酰基链子结构的系统简化的结构变体有助于确定安全性和有效佐剂活性的最低结构要求,并且从完全合成的QS-21(SQS-21)到我们的主要合成类似物,所需的合成步骤数量减少了50%以上。这些努力(现已完成)导致选择最佳QS-21类似物TiterQuil-1-0-5-5用于更正式的临床前开发,因为其结构简化,稳定性提高,效力一致,毒性减弱。核心知识产权是我们的三萜皂苷合成技术(TriSST)平台,涵盖了专利申请“三萜皂苷,合成方法和用途”申请号12/420,803下的合成方法以及新型物质组合物,以及我们受美国专利保护的专有半合成技术美国专利号8,283,456。TriSST由Memorial Sloan-Kettering Cancer Center(MSKCC)的大卫金博士等人开发,该技术已获得Adjuvance Technologies,Inc.的独家许可。TriSST是一种高度收敛的合成方法,其中QS-21中的四个结构域(支链三糖+三萜+线性四糖+脂肪酰基链)分别合成,然后组装以产生靶分子。每个结构域都可以独立修饰,然后组合以产生几乎无限数量的合理设计的QS-21类似物。最初完全合成的QS-21(SQS-21)在1期临床试验中显示出安全性和免疫活性。然后,我们使用TriSST在一系列系统的连续研究中制备和测试了100多种新型类似物。我们用于评估QS-21及其类似物的模型涉及针对一系列肽和碳水化合物癌抗原的KLH缀合物疫苗,测量针对这些抗原的抗体应答,以及在某些情况下测量针对MUC 1和KLH的T细胞应答。平行跟踪了这几种测定的结果,无一致的离群值。已证实所选类似物针对新型莱姆病OspC肽和肺炎球菌Prevnar 13疫苗的效力。在这里,我们建议通过在独立设施中按比例放大合成来进一步开发用于临床用途的TiterQuil-1-0-5-5。在这些研究的结论中,我们将证明TiterQuil-1-0-5-5合成可以扩大到接近商业要求的水平,并且与天然或合成QS-21相比,其具有改善的纯度、稳定性、安全性、易于生产性和免疫学效价(使用与传染病疫苗更相关的扩展抗原组)。这将为支持TiterQuil-1-0-5-5药物主文件(DMF)的2期SBIR申请及其在针对不同公共卫生问题的疫苗中的更广泛应用提供基础。具体目标1:合成2 g截短的QS-21类似物TiterQuil-1-0-5-5,这是目标2和3的足量。具体目标二:确认该规模放大批次TiterQuil-1- 0-5-5的纯度、稳定性和红细胞溶解能力,并根据DMF申请的要求进行正式的药理学/毒理学研究。具体目标3:使用靶向OspC肽的疫苗以及市售肺炎球菌结合物Prevnar-13,比较TiterQuil-1-0-5-5与天然和合成QS-21(SQS-21)的免疫效力和安全性。
英文摘要
DESCRIPTION (provided by applicant): Antitumor and anti-infectious disease vaccines require adjuvants in order to obtain optimal immunogenicity and therapeutic and protective efficacy. QS-21 is a natural saponin fraction that significantly out-performs other adjuvants in eliciting productive antibody and T-cell responses. It has remained the adjuvant of choice and has proven it's potency as immunological adjuvant in many cancer, infectious disease and degenerative disorder vaccine trials. Problems that have hampered the further development of QS-21 include adverse biological effects (that limit the tolerable dose), chemical instability, scarcity of the Quillaja saponaria tree (from which QS-21 is extracted) and variability of harvest yields from these trees. Recently, all of these liabilities have been overcome by our semisynthetic approach to QS-21 synthesis. This synthesis has also made molecular building blocks readily available for synthesis of modified and truncated QS-21 analogues. The replacement of unstable linkages within the native saponin with chemically robust functional groups has enhanced molecular stability. Structural variants incorporating systematic simplification of the peripheral sugar moieties and of the acyl chain substructure have aided in determining the minimal structural requirements for safety and potent adjuvant activity, and have decreased the required number of synthetic steps by over 50% from fully synthetic QS-21 (SQS-21) to our lead synthetic analogues. These efforts (now completed) have resulted in selection of the optimal QS-21 analogue TiterQuil-1-0-5-5 for more formal preclinical development because of its simplified structure, improved stability, consistent potency and attenuated toxicity. The core intellectual property is our Triterpene Saponin Synthesis Technology (TriSST) platform covering both the method of synthesis as well as novel compositions of matter under the patent application "TRITERPENE SAPONINS, METHODS OF SYNTHESIS, AND USES THEREOF" application number 12/420,803 as well as our proprietary semisynthetic technology which is protected by US patent U.S. Patent No. 8,283,456. TriSST was developed by Dr. David Gin et al at Memorial Sloan-Kettering Cancer Center (MSKCC) and this technology has been exclusively licensed by Adjuvance Technologies, Inc. TriSST is a highly convergent synthetic approach in which the four domains in QS-21 (branched trisaccharide + triterpene + linear tetrasaccharide + fatty acyl chain) are synthesized separately and then assembled to produce the target molecule. Each of the domains can be modified independently and then combined to produce a virtually infinite number of rationally designed QS-21 analogs. Initially fully synthetic QS-21(SQS-21) was shown to be safe and immunologically active in a Phase 1 clinical trial. We then used TriSST to prepare and test over 100 novel analogues in a systematic sequential series of studies. Our model for evaluating QS-21 and analogues has involved KLH-conjugate vaccines against a series of peptide and carbohydrate cancer antigens, measurement of antibody responses against these antigens, and in some cases measurement of T-cell responses against MUC1 and KLH. Results in these several assays have tracked in parallel with no consistent outliers. The potency of selected analogues has been confirmed against novel Lyme fever OspC peptides and pneumococcal Prevnar 13 vaccines. Here we propose to further develop TiterQuil-1-0-5-5 for clinical use by scaling up synthesis in an independent facility. At the conclusion of these studies we will have demonstrated that TiterQuil-1-0-5-5 synthesis can be scaled up to near commercially required levels and that it has improved purity, stability, safety, ease of manufacture, and immunologic potency (using an expanded panel of antigens more relevant for infectious disease vaccines) when compared to natural or synthetic QS-21. This will provide the basis for a Phase 2 SBIR application supporting a TiterQuil-1-0-5-5 drug master file (DMF) and its wider use in vaccines that target diverse public health concerns. Specific Aim 1: Synthesize 2 grams of truncated QS-21 analogue TiterQuil-1-0-5-5, a sufficient quantity for Aims 2 and 3. Specific Aim 2: Confirm purity, stability and erythrolytic capacity of this scaled up batch of TiterQuil-1- 0-5-5, and perfrm a formal pharmacology/toxicology study as required for a DMF application. Specific Aim 3: Compare the immunologic potency and safety of TiterQuil-1-0-5-5 with natural and synthetic QS-21(SQS-21) using vaccines targeting OspC peptide as well as the commercially available pneumococcal conjugate Prevnar-13.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Human Monoclonal Antibodies from Immunized Patient Lymphocytes
-
批准号:7405003
-
项目类别:
-
资助金额:$19.78万
-
财政年份:2008
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Immune Monitoring
-
批准号:7728800
-
项目类别:
-
资助金额:$12.5万
-
财政年份:2008
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Characterization of human antibodies to sialyl-Lewis A (sLeA) derived from patien
-
批准号:7801424
-
项目类别:
-
资助金额:$53.57万
-
财政年份:2008
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Pilot trial with a tetravalent conjugate vaccine against small cell lung cancer
-
批准号:7325719
-
项目类别:
-
资助金额:$20.18万
-
财政年份:2007
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Development of Antibody and T-Cell Inducing Vaccines
-
批准号:6952121
-
项目类别:
-
资助金额:$28.35万
-
财政年份:2005
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
Regulation by Immune Response to Vaccine by Botanicals
-
批准号:6946042
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2005
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER
-
批准号:6563801
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2002
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER
-
批准号:6423086
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2001
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER
-
批准号:6334957
-
项目类别:
-
资助金额:$26.78万
-
财政年份:2000
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
GLYCOLIPID AND PROTEIN VACCINES AGAINST CANCER
-
批准号:6300242
-
项目类别:
-
资助金额:$29.18万
-
财政年份:2000
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
DEVELOPMENT OF CANCER VACCINES
-
批准号:6102118
-
项目类别:
-
资助金额:$28.01万
-
财政年份:1999
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER
-
批准号:6203171
-
项目类别:
-
资助金额:$26.78万
-
财政年份:1999
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
DEVELOPMENT OF CANCER VACCINES
-
批准号:6269152
-
项目类别:
-
资助金额:$26.93万
-
财政年份:1998
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH ACTIVE AND PASSIVE IMMUNOTHERAPY AGAINST OVARIAN CANCER
-
批准号:6102612
-
项目类别:
-
资助金额:$26.78万
-
财政年份:1998
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
DEVELOPMENT OF CANCER VACCINES
-
批准号:6236654
-
项目类别:
-
资助金额:$25.13万
-
财政年份:1997
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CONSTRUCTION OF VACCINES AGAINST BREAST CANCER
-
批准号:2102174
-
项目类别:
-
资助金额:$19.46万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH A POLYVALENT BREAST CANCER VACCINE
-
批准号:2008350
-
项目类别:
-
资助金额:$28.97万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CONSTRUCTION OF VACCINES AGAINST BREAST CANCER
-
批准号:2102176
-
项目类别:
-
资助金额:$20.48万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CLINICAL TRIALS WITH A POLYVALENT BREAST CANCER VACCINE
-
批准号:2882392
-
项目类别:
-
资助金额:$30.59万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
CONSTRUCTION OF VACCINES AGAINST BREAST CANCER
-
批准号:2102175
-
项目类别:
-
资助金额:$19.92万
-
财政年份:1994
-
负责人:PHILIP O. LIVINGSTON
-
依托单位:
海外基金